Calliditas Therapeutics AB (publ)
CLTEF · OTC
5/31/2025 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $18 | $1,206,888 | $802,879 | $229,347 |
| % Growth | -100% | 50.3% | 250.1% | – |
| Cost of Goods Sold | $28 | $60,463 | $1,457 | $0 |
| Gross Profit | -$10 | $1,146,425 | $75,495 | $229,347 |
| % Margin | -55.8% | 95% | 9.4% | 100% |
| R&D Expenses | $0 | $502,223 | $39,752 | $39,519 |
| G&A Expenses | $1,892,959 | $331,040 | $24,819 | $23,149 |
| SG&A Expenses | $1,892,959 | $1,060,731 | $74,247 | $43,139 |
| Sales & Mktg Exp. | $0 | $727,740 | $49,378 | $19,855 |
| Other Operating Expenses | $0 | -$43,474 | -$2,066 | $671,144 |
| Operating Expenses | $1,892,959 | $1,519,480 | $111,933 | $753,803 |
| Operating Income | -$207 | -$373,055 | -$421,943 | -$524,456 |
| % Margin | -1,138.4% | -30.9% | -52.6% | -228.7% |
| Other Income/Exp. Net | $106 | -$83,962 | $12,526 | $11,083 |
| Pre-Tax Income | -$102 | -$457,017 | -$409,417 | -$513,373 |
| Tax Expense | $0 | $9,168 | $2,851 | -$3,836 |
| Net Income | -$102 | -$466,185 | -$39,514 | -$55,306 |
| % Margin | -558.6% | -38.6% | -4.9% | -24.1% |
| EPS | -0.058 | -8.69 | -7.78 | -9.84 |
| % Growth | 99.3% | -11.7% | 20.9% | – |
| EPS Diluted | -0.058 | -8.69 | -7.78 | -9.84 |
| Weighted Avg Shares Out | 16,986,259 | 53,672 | 52,991 | 50,829 |
| Weighted Avg Shares Out Dil | 16,985,181 | 53,672 | 53,023 | 50,829 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $2,803 | $774 |
| Interest Expense | $1 | $44,104 | $0 | $0 |
| Depreciation & Amortization | $272,367 | $4,234 | $202 | $28,722 |
| EBITDA | -$1,718,106 | -$386,350 | -$412,703 | -$494,119 |
| % Margin | -9,435,477% | -32% | -51.4% | -215.4% |